Radiographic pneumonia in young, highly febrile children with leukocytosis before and after universal conjugate pneumococcal vaccination

Pediatric Emergency Care

Volumn 25, Issue 1, 2009, Pages 1-7

  Rutman, Maia S ^a   Bachur, Richard ^b   Harper, Marvin B ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Leukocytosis; Pneumococcal vaccine; Pneumonia; Prevnar

Indexed keywords

PNEUMOCOCCUS VACCINE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; VACCINE;

ARTICLE; BLOOD CELL COUNT; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; EMERGENCY WARD; FEVER; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRESCHOOL CHILD; PREVALENCE; RADIOLOGIST; RETROSPECTIVE STUDY; STREPTOCOCCUS PNEUMONIAE; TACHYPNEA; THORAX RADIOGRAPHY; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; EMERGENCY HEALTH SERVICE; FEMALE; HOSPITAL; INFANT; MALE; RADIOGRAPHY; STATISTICS; UNITED STATES; VACCINATION;

BOSTON; CHILD, PRESCHOOL; COHORT STUDIES; EMERGENCY SERVICE, HOSPITAL; FEMALE; FEVER; HOSPITALS, PEDIATRIC; HOSPITALS, URBAN; HUMANS; INFANT; LEUKOCYTOSIS; MALE; PNEUMOCOCCAL VACCINES; PNEUMONIA; PREVALENCE; RETROSPECTIVE STUDIES; VACCINATION; VACCINES, CONJUGATE;

EID: 65249087450     PISSN: 07495161     EISSN: None     Source Type: Journal    
DOI: 10.1097/PEC.0b013e318191dab2     Document Type: Article

References (41)

1. Shuttleworth DB, Channey E. Leukocyte count in childhood pneumonia. Am JDis Child. 1971;122:393-396.
2. Mazur LJ, Kline MW, Lorin MI. Extreme leukocytosis in patients presenting to a pediatric emergency department. Pediatr Emerg Care. 1991;7:215-218.
3. Kramer MS, Tange SM, Mills EL, et al. Role of the complete blood count in detecting occult focal bacterial infection in the young febrile child. J Clin Epidemiol. 1993;46(4):349-357.
4. Ryan JG, Bareta I, Ward MF, et al. The utility of the WBC count to predict abnormal chest radiographs in febrile children from 90 days to 36 months of age (abstract). Ann Emerg Med. 2004;44(4):S110.
5. Murphy CG, van de Pol AC, Harper MB, et al. Clinical predictors of occult pneumonia in the febrile child. Acad Emerg Med. 2007; 14(3):243-249.
6. Kline MW, Smith EO, Kaplan SL, et al. Effects of causative organism and presence or absence of meningitis on white blood cell counts in children with bacteremia. J Emerg Med. 1988;6(1):33-35.
7. Ruuskanen O, Nohynek H, Ziegler T, et al. Pneumonia in childhood: Etiology and response to antimicrobial therapy. Eur J Clin Microbiol Infect Dis. 1992;11:217-223.
8. Totapally BR, Walsh WT. Pneumococcal bacteremia in childhood. Chest. 1998;113:1207-1214.
9. Stoll ML, Rubin LG. Incidence of occult bacteremia among highly febrile young children in the era of the pneumococcal conjugate vaccine. Arch Pediatr Adolesc Med. 2004;158:671-675.
10. Bachur R, Perry H, Harper MB. Occult pneumonias: empiric chest radiographs in febrile children with leukocytosis. Ann Emerg Med. 1999;33(2):166-173.
11. Black SB, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002; 21(9):810-815.
12. Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349(14):1341-1348.
13. Kaplan SL, Mason EO, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004;113:443-449.
14. Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005;365:1139-1146.
15. MassHealth Prescriber Bulletin 3, April 2000. To: Physicians, outpatient hospitals, and nurse practitioners participating in MassHealth. From: Mark E. Reynolds, Acting Commissioner. Re: Pneumococcal Conjugate Vaccine. Available at: http://www.mass.gov/Eeohhs2/docs/masshealth/ bull-2000/psc-3.pdf.
16. Pneumococcal Vaccine Now Available! [press release June 26, 2000] Massachusetts Department of Public Health, Massachusetts Immunization Program.
17. National Immunization Program. Estimated vaccination coverage with individual vaccines and selected vaccination series among children 19-35 months of age by state, US, National Immunization Survey (NIS), 2002-2005. Available at: http://www.cdc.gov/nip/coverage/NIS/03/ toc-03.htm http://www.cdc.gov/nip/ coverage/NIS/04/toc-04.htm http:// www.cdc.gov/nip/coverage/NIS/05/toc-05.htm.
18. Lynch T, Plattaw R, Gouin S, et al. Can we predict which children with clinically suspected pneumonia will have the presence of focal infiltrates on chest radiographs? Pediatrics. 2004;113(3):186-189.
19. Frederick RC. The clinical diagnosis of infantile pneumonia. Ann Emerg Med. 2006;48(5):627-630.
20. Jadavji T, Law B, Lebel MH, et al. A practical guide for the diagnosis and treatment of pediatric pneumonia. Can Med Assoc J. 1997;156 (suppl): S703-711.
21. Rothrock SG, Green SM, Fanelli JM, et al. Do published guidelines predict pneumonia in children presenting to an urban ED? Pediatr Emerg Care. 2001;17(4):240-243.
22. Black SB, Shinefield HR, Hansen J, et al. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2001;20:1105-1107.
23. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348(18): 1737-1746.
24. O'Brien KL, Moulton LH, Reid R, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomized trial. Lancet. 2003;362(9381):355-361.
25. Hsu K, Pelton S, Karumuri S, et al J. Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine. Pediatr Infect Dis J. 2005;24(1):17-23.
26. Juven T, Mertsola J, Waris M, et al. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J. 2000; 19:293-298.
27. Heiskanen-Kosma T, Korppi M, Jokinen C, et al. Etiology of childhood pneumonia: serologic results of a prospective, population-based study. Pediatr Infect Dis J. 1998;17(11):986-991.
28. Wubbel L, Muniz L, Ahmed A, et al. Etiology and treatment of community-acquired pneumonia in ambulatory children. Pediatr Infect Dis J. 1999;18:98-104.
29. Overturf GD. American Academy of Pediatrics. Committee on Infectious Diseases. Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis. Pediatrics. 2000; 106 (2 pt 1):367-376.
30. Zhao GM, Glack S, Shinefield H, et al. Serotype distribution and antimicrobial resistance patterns in Streptococcus pneumoniae isolates from hospitalized pediatric patients with respiratory infections in Shanghai, China. Pediatr Infect Dis J. 2003;22(8): 739-742.
31. Esposito S, Madore DV, Gironi S, et al. Theoretic coverage of heptavalent pneumococcal conjugate vaccine in the prevention of community-acquired pneumonia in children in Italy. Vaccine. 2003;21(21-22):2704-2707.
32. Heiskanen-Kosma T, Korppi M, Leinonen M. Serologically indicated pneumococcal pneumonia in children: a population-based study in primary care settings. Acta Pathol Microbiol Immunol Scand. 2003; 110(10):945-950.
33. Michelow IC, Olsen K. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics. 2004;113(4):701-707.
34. Poehling KA, Lafleur BJ, Szilagyi PG, et al. Population-based impact of pneumococcal conjugate vaccine in young children. Pediatrics. 2004;114(3):755-761.
35. Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunization with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007; 369(9568): 1179-1186.
36. Baraff LJ, Bass JW, Fleisher GR, et al. Practice guideline for the management of infants and children 0 to 36 months of age with fever without source. Agency for Health Care Policy and Research. Ann Emerg Med. 1993;22(7):1198-1210.
37. Harper MB, Fleisher GR. Occult bacteremia in the 3-month-old to 3-year-old age group. Pediatr Ann. 1993;22(3):487-493.
38. Lee GM, Fleisher GR, Harper MB. Management of febrile children in the age of the conjugate pneumococcal vaccine: a cost-effectiveness analysis. Pediatrics. 2001;108(4):835-844.
39. Baraff LJ. Management of fever without source in infants and children. Ann Emerg Med. 2000;36(6):602-614.
40. Yamamoto L. Revising the decision analysis for febrile children at risk for occult bacteremia in a future era of widespread pneumococcal immunization. Clin Pediatr. 2001;40(11):583-594.
41. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. MMWR Morb Mortal Wkly Rep. 2005;54(36):893-897.